Enveric Biosciences GAAP EPS of -$1.08
Seeking Alpha News (Fri, 15-May 8:41 AM ET)
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
Business Wire (Fri, 15-May 8:00 AM ET)
Business Wire (Wed, 13-May 8:00 AM ET)
Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
Business Wire (Tue, 5-May 8:00 AM ET)
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
PRNewswire (Tue, 28-Apr 7:33 AM ET)
Enveric Biosciences to Participate in a Panel Discussion at Needham's Virtual Psychedelics Forum
Business Wire (Tue, 21-Apr 8:00 AM ET)
Market Chameleon (Mon, 20-Apr 5:52 AM ET)
Market Chameleon (Mon, 20-Apr 3:51 AM ET)
Business Wire (Fri, 17-Apr 6:28 PM ET)
Business Wire (Thu, 16-Apr 8:00 PM ET)
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
Enveric Biosciences trades on the NASDAQ stock market under the symbol ENVB.
As of May 15, 2026, ENVB stock price declined to $2.25 with 124,393 million shares trading.
ENVB has a beta of 0.21, meaning it tends to be less sensitive to market movements. ENVB has a correlation of 0.00 to the broad based SPY ETF.
ENVB has a market cap of $4.47 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ENVB traded as high as $1,256.40 and as low as $1.71.
The top ETF exchange traded funds that ENVB belongs to (by Net Assets): PSIL.
ENVB has underperformed the market in the last year with a price return of -85.1% while the SPY ETF gained +26.4%. ENVB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +7.1% and -43.6%, respectively, while the SPY returned +8.7% and +2.6%, respectively.
ENVB support price is $1.97 and resistance is $2.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENVB shares will trade within this expected range on the day.